Targeted molecular therapy of GBM

Brain Pathology

Volumn 13, Issue 1, 2003, Pages 52-61

  Mischel, Paul S ^a   Cloughesy, Timothy F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BEVACIZUMAB; CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; EPIDERMAL GROWTH FACTOR RECEPTOR VIII ANTIBODY; ERLOTINIB; GEFITINIB; IMATINIB; IMC IC11; IMMUNOLIPOSOME; IODINE 125; LIGAND; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; ONYX 015; PELITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN TP 53; PSEUDOMONAS EXOTOXIN; RAPAMYCIN; RITUXIMAB; SEMAXANIB; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; WORTMANNIN;

ANGIOGENESIS; BRAIN CANCER; BREAST CANCER; CANCER INVASION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENOMICS; GLIOBLASTOMA; HUMAN; IMMUNOTHERAPY; MOLECULAR BIOLOGY; NONHODGKIN LYMPHOMA; ONCOGENE; ONCOGENE RAS; REVIEW; TUMOR SUPPRESSOR GENE; VIRAL GENE THERAPY;

EID: 0037245929     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2003.tb00006.x     Document Type: Review

References (89)

1. Adjei AA, Davis JN, Bruzek LM, Erlichman C, Kaufmann SH (2001) Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res 7:1438-1445.
2. Ansher SS, Scharf R (2001) The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute: industry collaborations in new agent development. Ann N Y Acad Sci 949:333-340.
3. Bello L, Lucini V, Carrabba G, Giussani C, Machluf M, Pluderi M, Nikas D, Zhang J, Tomei G, Villani RM, et al (2001) Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2. Cancer Res 61:8730-8736.
4. Boehm T, Folkman J, Browder T, O'Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407.
5. Brady LW, Miyamoto C, Woo DV, Rackover M, Emrich J, Bender H, Dadparvar S, Steplewski Z, Koprowski H, Black P, et al (1992) Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 22:225-230
6. Brat DJ, Van Meir EG (2001) Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. Am J Pathol 158:789-796.
7. Carter P (2001) Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1:118-129.
8. Chavakis E, Dimmeler S (2002) Regulation of endothelial cell survival and apoptosis during angiogenesis. Arterioscler Thromb Vasc Biol 22:887-893.
9. Cheng Y, Ng HK, Ding M, Zhang SF, Pang JC, Lo KW (1999) Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors. J Neuropathol Exp Neurol 58:120-128.
10. Choe G, Park JK, Joubin-Steele L, Kremen TJ, Liau LM, Vinters HV, Cloughesy TF, Mischel PS (2002) Active MMP-9 expression is associated with primary glioblastoma subtype. Clinical Cancer Research 8:2894-2901.
11. Cloughesy TF, Kuhn J, Wen P, Chang SM, Schiff D, Greenberg H, Junck L, Robins I, DeAngelis L, Yung A, Groves et al (2002) Phase II trial of R11577 (Zarnestra) in patients with recurrent glioma not taking enzyme inducing antiepileptic drugs (EIAED): a North American Brain Tumor Consortium (NABTC) report. Proc Am Soc Clin Oncol
12. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648.
13. Coffey MC, Strong JE, Forsyth PA, Lee PW (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282:1332-1334.
14. Drevs J, Muller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H, Konerding MA, Allegrini PR, Wood J, Hennig J et al (2002) PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62:4015-4022.
15. Druker BJ (2002) Perspectives on the development of a molecularly targeted agent. Cancer Cell 1:31-36.
16. Ekstrand AJ, Sugawa N, James CD, Collins VP (1992) Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A 89:4309-4313.
17. Feldkamp MM, Lala P, Lau N, Roncari L, Guha A (1999) Expression of activated epidermal growth factor receptors, Ras- guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 45:1442-1453.
18. Feldkamp MM, Lau N, Guha A (1999) The farnesyltransferase inhibitor L-744,832 inhibits the growth of astrocytomas through a combination of antiproliferative, antiangiogenic, and proapoptotic activities. Ann N Y Acad Sci 886:257-260.
19. Fernandez N, Duffour MT, Perricaudet M, Lotze MT, Tursz T, Zitvogel L (1998) Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects. Cytokines Cell Mol Ther 4:53-65.
20. Folkman J (1999) Angiogenesis research: from laboratory to clinic. Forum (Genova) 9:59-62.
21. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, et al (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (FIk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99-106.
22. Foulon CF, Reist CJ, Bigner DD, Zalutsky MR (2000) Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. Cancer Res 60:4453-4460.
23. Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383-1387.
24. Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H, Hallahan DE (2001) Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61:2413-2419.
25. Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacombe MJ, Bressac De-Paillerets B, Barrois M, Feunteun J, Kirn DH et al (2002) Oncolytic activity of the E1 B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res 62:764-772.
26. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for FIk-1/KDR activation. J Biol Chem 273:30336-30343.
27. Glass TL, Liu TJ, Yung WK (2000) Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336. Neuro-oncol 2:151-158.
28. Gurney JG, Kadan-Lottick N (2001) Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr Opin Oncol 13:160-166.
29. Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW (1998) p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med 4:1068-1072.
30. Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN, von Deimling A (1997) Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 7:871-875.
31. Hills D, Rowlinson-Busza G, Gullick WJ (1995) Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody. Int J Cancer 63:537-543.
32. Hunt S (2001) Technology evaluation: IMC-lC11, ImClone Systems. Curr Opin Mol Ther 3:418-424.
33. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD (1999) Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 100:1423-1431.
34. Jiang K, Coppola D, Crespo NC, Nicosia SV, Hamilton AD, Sebti SM, Cheng JQ (2000) The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 20:139-148.
35. Joki T, Machluf M, Atala A, Zhu J, Seyfried NT, Dunn IF, Abe T, Carroll RS, Black PM (2001) Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol 19:35-39.
36. Jung V, Romeike BF, Henn W, Feiden W, Moringlane JR, Zang KD, Urbschat S (1999) Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells. J Neuropathol Exp Neurol 58:993-999.
37. Karp JE, Kaufmann SH, Adjei AA, Lancet JE, Wright JJ, End DW (2001) Current status of clinical trials of farnesyltransferase inhibitors. Curr Opin Oncol 13:470-476.
38. Kilic T, Alberta JA, Zdunek PR, Acar M, lannarelli P, O'Reilly T, Buchdunger E, Black PM, Stiles CD (2000) Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2- phenylaminopyrimidine class. Cancer Res 60:5143-5150.
39. Kirn D (2000) Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 19:6660-6669.
40. Kirn D (2001) Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther 1:525-538.
41. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215-225; discussion 226-219.
42. Kleihues P, Ohgaki H (1999) Primary and secondary glioblastomas: from concept to clinical diagnosis. Neurooncol 1:44-51.
43. Kuan CT, Wikstrand CJ, Bigner DD (2001) EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8:83-96.
44. Lawler J (2002) Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6:1-12.
45. Levin VA (1999) Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: the past decade and where we are heading. Neuro-oncol 1:69-80.
46. Liau LM, Lallone RL, Seitz RS, Buznikov A, Gregg JP, Kornblum HI, Nelson SF, Bronstein JM (2000) Identification of a human glioma-associated growth factor gene, granulin, using differential immuno-absorption. Cancer Res 60:1353-1360.
47. Liu W, James CD, Frederick L, Alderete BE, Jenkins RB (1997) PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 57:5254-5257.
48. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA (2002) Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62:3729-3735.
49. Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I (1996) Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci U S A 93:14815-14820.
50. Markert JM, Gillespie GY, Weichselbaum RR, Roizman B, Whitley RJ (2000) Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol 10:17-30.
51. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ (1999) Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 26:79-87.
52. Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ, et al (2001) Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 61:5349-5354.
53. Nagane M, Lin H, Cavenee WK, Huang HJ (2001) Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett 162 Suppl:S17-S21.
54. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135-1149.
55. Nelson NJ (1999) Angiogenesis research is on fast forward. J Natl Cancer Inst 91:820-822.
56. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98:10314-10319.
57. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 91:7727-7731.
58. Nozaki M, Tada M, Kobayashi H, Zhang CL, Sawamura Y, Abe H, Ishii N, Van Meir EG (1999) Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro-oncol 1:124-137.
59. Oehler MK, Bicknell R (2000) The promise of anti-angiogenic cancer therapy. Br J Cancer 82:749-752.
60. O'Reilly MS, Holmgren L, Chen C, Folkman J (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689-692.
61. Park JW (2002) Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 4:95-99
62. Rosen LS (2002) Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 9:36-44.
63. Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, Hale LP, Small C, Dranoff G, Friedman AH et al (2000) Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 97:7503-7508.
64. Schmidt EE, Ichimura K, Goike HM, Moshref A, Liu L, Collins VP (1999) Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. J Neuropathol Exp Neurol 58:1170-1183.
65. Shawver LK, Slamon D, Ullrich A (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1:117-123.
66. Siwak DR, Tari AM, Lopez-Berestein G (2002) The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin Cancer Res, 8:1172-1181
67. 2002. Clin Cancer Res 8:955-956.
68. Slamon D, Pegram M (2001) Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28:13-19.
69. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792.
70. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, et al (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246-1256.
71. Sundberg C, Nagy JA, Brown LF, Feng D, Eckelhoefer IA, Manseau EJ, Dvorak AM, Dvorak HF (2001) Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am J Pathol 158:1145-1160.
72. Tenan M, Fulci G, Albertoni M, Diserens AC, Hamou MF, El Atifi-Borel M, Feige JJ, Pepper MS, Van Meir EG (2000) Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells. J Exp Med 191:1789-1798.
73. Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, Kleihues P, Ohgaki H (1998) PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 57:684-689.
74. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J (2001) Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 21:499-512.
75. Vajkoczy P, Menger MD, Vollmar B, Schilling L, Schmiedek P, Hirth KP, Ullrich A, Fong TA (1999) Inhibition of tumor growth, angiogenesis, and microcirculation by the novel FIk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1:31-41.
76. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3- Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501.
77. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726.
78. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN (1993) Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3:19-26.
79. Wang QC, Pai LH, Debinski W, FitzGerald DJ, Pastan I (1993) Polyethylene glycol-modified chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin. Cancer Res 53:4588-4594.
80. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6:217-223; discussion 223-214.
81. Wen PY, Yung WK, Hess K, Silberman S, Hayes M, Schiff D, Lieberman F, Cloughesy TF, DeAngeles LM, Chang SM et al (2002) Phase I study of STI571 (Gleevec) for patients with recurrent malignant gliomas and meningiomas (NABTC 99-08). Proc Am Soc Clin Oncol:
82. Wikstrand CJ, Cokgor I, Sampson JH, Bigner DD (1999) Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev 18:451-464.
83. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, et al (1995) Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55:3140-3148.
84. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD (1997) Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57:4130-4140.
85. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD (1998) The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol 4:148-158.
86. Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, Brasher PM, Shi ZQ, Johnston RN, Nishikawa S, Lee PW, et al (2001) Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 93:903-912.
87. Yung WK, Friedman H, Jackson E, Provenzale J, Leeds N, Conrad C, Walker A, Henry A, Huang J, Laurent D, Dugan M (2002) A phase I trial of PTK787/Zk 22584 (PTK/ZK), a novel oral VEGFR TK inhibitor in recurrent glioblastoma. Proc Am Soc Clin Oncol
88. Zagzag D, Capo V (2002) Angiogenesis in the central nervous system: a role for vascular endothelial growth factor/vascular permeability factor and tenascin-C. Common molecular effectors in cerebral neoplastic and non-neoplastic "angiogenic diseases". Histol Histopathol 17:301-321.
89. Zhang Y, Zhu C, Pardridge WM (2002) Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol Ther 6:67-72.